Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) – Pipeline Review, H2 2017’, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Gastrointestinal, Central Nervous System, Genito Urinary System And Sex Hormones, Hematological Disorders, Hormonal Disorders and Metabolic Disorders under development targeting Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)

The report reviews Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics and enlists all their major and minor projects

The report assesses Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Apexigen Inc

Apogenix GmbH

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celldex Therapeutics Inc

Denceptor Therapeutics Ltd

F. Hoffmann-La Roche Ltd

Johnson & Johnson

Kyowa Hakko Kirin Co Ltd

Novartis AG

Seattle Genetics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Overview 8

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Development 9

Products under Development by Stage of Development 9

Products under Development by Therapy Area 10

Products under Development by Indication 11

Products under Development by Companies 14

Products under Development by Universities/Institutes 19

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Assessment 21

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Companies Involved in Therapeutics Development 27

AbbVie Inc 27

Apexigen Inc 28

Apogenix GmbH 28

Boehringer Ingelheim GmbH 29

Bristol-Myers Squibb Company 29

Celldex Therapeutics Inc 30

Denceptor Therapeutics Ltd 30

F. Hoffmann-La Roche Ltd 31

Johnson & Johnson 32

Kyowa Hakko Kirin Co Ltd 33

Novartis AG 34

Seattle Genetics Inc 35

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Drug Profiles 36

2C-10 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

ABBV-428 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

APG-1233 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

APX-005M - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

BI-655064 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Bispecific Monoclonal Antibody to Agonize CD40 for Oncology - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

bleselumab - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

BMS-986090 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

CDX-1140 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

CFZ-533 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

DNP-005 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

emactuzumab + RG-7876 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

FFP-104 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

JNJ-7107 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

KGYY-15 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Monoclonal Antibodies to Agonize CD40 and FCGR2B for B-cell Lymphoma and Melanoma - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Monoclonal Antibody Conjugate to Target CD40 for Pancreatic Cancer - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

RG-7876 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

RG-7876 + vanucizumab - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

SEA-CD40 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Dormant Products 63

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Discontinued Products 65

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Product Development Milestones 66

Featured News & Press Releases 66

Jul 17, 2017: Apexigen Announces First Patient Dosed in Phase 1b/2 Clinical Trial of APX005M in Combination with Opdivo (nivolumab) in Advanced Solid Tumors 66

May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ADC-1013 66

Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ADC-1013 at PEGS conference in Boston, May 4 67

Apr 03, 2017: Phase I Clinical Trial Completes Using Cell Line Expertise at Cobra Biologics 67

Mar 23, 2017: Alligator announces completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013 68

Mar 21, 2017: Phase 1/2 Clinical Trial of Apexigen’s APX005M in Combination with Pembrolizumab (Keytruda) Opens for Metastatic Melanoma Patients 68

Dec 05, 2016: Celldex Presents Data on CDX-1140, a Novel CD40 Agonist Antibody for Hematologic and Solid Malignancies, at the American Society of Hematology Annual Meeting 69

Nov 14, 2016: Celldex Presents Data on New Product Candidate, CDX-1140, a Novel CD40 Agonist Antibody 69

Oct 12, 2016: Alligator Bioscience informs that dosing has started in a second clinical phase I study with the CD40 Agonistic Immuno-Oncology Antibody ADC-1013 70

Apr 22, 2016: Alligator Bioscience Recieves First Milestone Payment for ADC-1013 70

Apr 18, 2016: Seattle Genetics Highlights Data on SEA-CD40 at the American Association for Cancer Research Annual Meeting 71

Apr 13, 2016: Apexigen to Present Data on Its Novel Immuno-Oncology Program APX005M at Upcoming Cancer Conferences 71

Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn’s Disease with anti-CD40 Monoclonal Antibody 72

Nov 17, 2015: Apexigen Presents Positive Data for APX005M in Podium Presentation at Immune Checkpoint Inhibitors (ICI) Europe 72

Nov 06, 2015: Apexigen Presents Preclinical Data from Novel Immuno-Oncology Candidate APX005M at SITC 2015 Meeting 73

Appendix 74

Methodology 74

Coverage 74

Secondary Research 74

Primary Research 74

Expert Panel Validation 74

Contact Us 74

Disclaimer 75

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Indications, H2 2017 11

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 13

Number of Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 15

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 18

Number of Products under Investigation by Universities/Institutes, H2 2017 19

Products under Investigation by Universities/Institutes, H2 2017 20

Number of Products by Stage and Mechanism of Actions, H2 2017 22

Number of Products by Stage and Route of Administration, H2 2017 24

Number of Products by Stage and Molecule Type, H2 2017 26

Pipeline by AbbVie Inc, H2 2017 27

Pipeline by Apexigen Inc, H2 2017 28

Pipeline by Apogenix GmbH, H2 2017 28

Pipeline by Boehringer Ingelheim GmbH, H2 2017 29

Pipeline by Bristol-Myers Squibb Company, H2 2017 29

Pipeline by Celldex Therapeutics Inc, H2 2017 30

Pipeline by Denceptor Therapeutics Ltd, H2 2017 30

Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 31

Pipeline by Johnson & Johnson, H2 2017 32

Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 33

Pipeline by Novartis AG, H2 2017 34

Pipeline by Seattle Genetics Inc, H2 2017 35

Dormant Products, H2 2017 63

Dormant Products, H2 2017 (Contd..1), H2 2017 64

Discontinued Products, H2 2017 65

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Top 10 Indications, H2 2017 11

Number of Products by Mechanism of Actions, H2 2017 21

Number of Products by Stage and Mechanism of Actions, H2 2017 21

Number of Products by Routes of Administration, H2 2017 23

Number of Products by Stage and Routes of Administration, H2 2017 23

Number of Products by Molecule Types, H2 2017 25

Number of Products by Stage and Molecule Types, H2 2017 25

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports